Second Sight Medical Products

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company was founded on May 22,2003 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Vivani Medical Inc

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the “Company” or “Vivani”) announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol “VANI” will commence today. Vivani is the combination of Nano Precision Medical, Inc. (“NPM”) and Second Sight Medical Products, Inc. Closing of the merger was completed and announced yesterday, August 30, 2022. Vivani leverages proprietary technologies to deve

Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc.(NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. (“NPM”). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-te

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

A 1-for-3 reverse split of Second Sight Medical Products (EYES) has gone into effect. These are the details.

Second Sight Medical Products (EYES) Stock: 1-For-3 Split Goes Into Effect

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. A

Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (“NIH”) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the “Orion Trial”), grant 5UH3NS10344

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight”), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. (“NPM”), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States. As previously announced, Sec

Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Wilmington, Delaware--(Newsfile Corp. - February 18, 2022) - Rigrodsky Law, P.A. announces that it is investigating Second Sight Medical Products, Inc. ("Second Sight") (NASDAQ: EYES) regarding possible breaches of fiduciary duties and other violations of law related to Second Sight's agreement to be acquired by Nano Precision Medical, Inc. ("Nano"). Under the terms of the agreement, Nano's shareholders will receive a total of 134 million shares of Second Sight common stock.To learn more about this...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Second Sight Medical Products, Inc. Merger

NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

SECOND SIGHT MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Second Sight Medical Products, Inc. - EYES

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Second Sight Medical Products, Inc. (NASDAQ: EYES) and Nano Precision Medical, Inc. is fair to Second Sight shareholders. Halper Sadeh encourages Second Sight shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether S

EYES Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Second Sight Medical Products, Inc. Is Fair to Shareholders

American Rebel Holdings Inc

Splash Beverage Group

What you need to know about trading penny stocks on February 8th The post Trading Penny Stocks? Top Stock Market News For February 8th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News For February 8th, 2022

EYES stock is up 15% today on news that Second Sight Medical is making a strategic acquisition. Here's what to know.

EYES Stock Pops on Biotech Merger Plans. 5 Things to Know.

AstraZeneca

Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction.  Second Sight Medical develops implantable visual prosthetics.

Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical

LOS ANGELES & EMERYVILLE, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and devi

Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprosthese

Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study

DarkPulse, Inc.

India Globalization Capital

PainReform Ltd.

Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?

Highest Volume Penny Stocks to Watch Today? Check These 4 Out

EYES stock is set for another day of double-digit gains after the European patent agency approved the company's application. The post EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight appeared first on InvestorPlace.

EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by over 15% pre-market. This is why it happened.

EYES Stock Increases Over 15% Pre-Market: Why It Happened

Advaxis

Rigel Pharmaceuticals

SenesTech

Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?

Top Biotech Penny Stocks to Buy This Week? 9 To Watch

Dare Bioscience

GT Biopharma Inc

Predictive Oncology Inc

Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?

Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underw

Second Sight Medical Products Announces Closing of Public Offering

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions an

Second Sight Medical Products Announces Pricing of Public Offering

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no a

Second Sight Medical Products Announces Proposed Public Offering of Common Stock

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021. Second Sight held its annual meeting online due to the COVID-19 pandemic. 60.98% of shareholders were present online or by proxy. Shareholders voted on four proposals: (1) elect

Second Sight Medical Products Announces Results of its 2021 Annual Meeting

Corbus Pharmaceuticals Holdings

Tyme Technologies

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks That Are Popular on Reddit Right Now

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (NIH) of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant UH3NS103442.

News for Second Sight Medical Products Stock (EYES)